126 related articles for article (PubMed ID: 24473270)
1. A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates.
Sun Y; Zhao D; Wang G; Jiang Q; Guo M; Kan Q; He Z; Sun J
Asian J Pharm Sci; 2019 Nov; 14(6):631-639. PubMed ID: 32104489
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumor specific drug release by hypoxia sensitive dual-prodrugs based on 2-nitroimidazole.
Tsuji T; Tsunematsu H; Imanishi M; Denda M; Tsuchiya K; Otaka A
Bioorg Med Chem Lett; 2023 Oct; 95():129484. PubMed ID: 37716415
[TBL] [Abstract][Full Text] [Related]
3. A fluorescent gemcitabine prodrug that follows a nucleoside transporter-independent internalization and bears enhanced therapeutic efficacy with respect to gemcitabine.
Vrettos E; Kyrkou S; Zoi V; Giannakopoulou M; Chatziathanasiadou M; Kanaki Z; Agalou A; Bistas VP; Kougioumtzi A; Karampelas T; Diamantis D; Murphy C; Beis D; Klinakis A; Tamvakopoulos C; Kyristis A; Alexiou G; Tzakos A
Chemistry; 2024 Jun; ():e202401327. PubMed ID: 38941241
[TBL] [Abstract][Full Text] [Related]
4. The evolution of nucleosidic analogues: self-assembly of prodrugs into nanoparticles for cancer drug delivery.
Baroud M; Lepeltier E; Thepot S; El-Makhour Y; Duval O
Nanoscale Adv; 2021 Apr; 3(8):2157-2179. PubMed ID: 36133769
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of gemcitabine oral absorption as determined by in situ intestinal perfusions in mice.
Thompson BR; Hu Y; Smith DE
Biochem Pharmacol; 2019 Oct; 168():57-64. PubMed ID: 31207211
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic Cancer Chemoresistance to Gemcitabine.
Amrutkar M; Gladhaug IP
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29144412
[TBL] [Abstract][Full Text] [Related]
7. How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.
Kell DB; Oliver SG
Front Pharmacol; 2014; 5():231. PubMed ID: 25400580
[TBL] [Abstract][Full Text] [Related]
8. Modern prodrug design for targeted oral drug delivery.
Dahan A; Zimmermann EM; Ben-Shabat S
Molecules; 2014 Oct; 19(10):16489-505. PubMed ID: 25317578
[TBL] [Abstract][Full Text] [Related]
9. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
10. Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs.
Fàbrega C; Clua A; Eritja R; Aviñó A
Curr Med Chem; 2023; 30(11):1304-1319. PubMed ID: 34844535
[TBL] [Abstract][Full Text] [Related]
11. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.
Tsume Y; Borras Bermejo B; Amidon GL
Pharmaceuticals (Basel); 2014 Jan; 7(2):169-91. PubMed ID: 24473270
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.
Tsume Y; Hilfinger JM; Amidon GL
Mol Pharm; 2008; 5(5):717-27. PubMed ID: 18652477
[TBL] [Abstract][Full Text] [Related]
13. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
[TBL] [Abstract][Full Text] [Related]
14. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
